Contineum Therapeutics (NASDAQ:CTNM) Earns Outperform Rating from Analysts at Royal Bank of Canada

Research analysts at Royal Bank of Canada began coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research note issued to investors on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $30.00 price target on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 87.50% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. Morgan Stanley started coverage on shares of Contineum Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $25.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Contineum Therapeutics in a research report on Tuesday. They set a “buy” rating and a $29.00 target price for the company.

Contineum Therapeutics Trading Up 1.8 %

CTNM opened at $16.00 on Tuesday. Contineum Therapeutics has a 12 month low of $13.90 and a 12 month high of $16.05.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).